Supercharged immune cells take aim at cancer and viruses in one shot

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

INCLUSION CRITERIA: 1. Any patient regardless of sex or age with CD19+ B-ALL undergoing allogeneic HSCT (Group A) OR Any patient regardless of sex or age with CD19+ B-CLL or NHL undergoing allogeneic HSCT (Group B). AND With minimal residual disease (MRD) or relapse post-HSCT (for the phase I dose escalation) OR With no evidence of ALL or CLL/NHL post-HSCT (to be included in the expansion cohort 2. Patients with life expectancy greater than or equal to 6 weeks 3. Patients with a Karnofsky/Lansky score greater than or equal to 50 4. Donor HIV negative 5. Patient or parent/guardian capable of providing informed consent 6. Patients with bilirubin 2x normal or less, AST 3x normal or less, creatinine less than or equal to 2x normal for age and Hgb greater than 8.0 7. Pulse oximetry of greater than 90% on room air 8. Sexually active patients must be willing to utilize one of the more effective birth control methods for 6 months after the CTL infusion. The male partner should use a condom. 9. Available allogeneic CD19CAR transduced tri-virus-specific cytotoxic T lymphocytes with greater than or equal to15% expression of CD19CAR determined by flow-cytometry and greater than 10% killing of one or more viral antigen pulsed targets in a cytotoxicity assay at an effector:target ratio of 20:1.\* 10. Patients should have been off other investigational antiviral or antitumor therapy for one month prior to entry in this study. * Note: Cell dose is based on total cell numbers and not individual antivirus or antileukemic cell numbers. EXCLUSION CRITERIA: 1. Severe intercurrent infection 2. Evidence of graft versus host disease \>grade II 3. Pregnant or lactating 4. History of hypersensitivity reactions to murine protein-containing products. 5. Currently taking corticosteroids for therapy of GVHD.